Luis Palacios, MD
Adult Medicine · Dallas, TXNPI 1487614392
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations.
Across 135 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$477
- GSK$398
- AstraZeneca$307
- Amgen$233
- Novo Nordisk$188
- Boehringer Ingelheim$179
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,68196%
- Education$1124%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $477 |
| GSK | 14 | $398 |
| AstraZeneca | 19 | $307 |
| Amgen(2 entities) | 8 | $233 |
| Novo Nordisk | 11 | $188 |
| Boehringer Ingelheim | 15 | $179 |
| Merz North America, Inc. | 2 | $173 |
| AbbVie | 9 | $154 |
| Bayer | 1 | $116 |
| Exact Sciences | 6 | $89 |
| Medtronic | 1 | $74 |
| Pfizer | 3 | $59 |
| Mindray DS USA, Inc. | 1 | $57 |
| Merck | 4 | $54 |
| Phadia US Inc. | 3 | $52 |
| Abbott | 2 | $33 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Metuchen Pharmaceuticals | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,793 in reported general payments places this provider in the 80th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $45,947 |
| OzempicSemaglutide | 29 | $43,997 |
| FarxigaDapagliflozin Propanediol | 29 | $35,404 |
| JanuviaSitagliptin Phosphate | 22 | $30,807 |
| JardianceEmpagliflozin | 16 | $27,375 |
| LinzessLinaclotide | 12 | $19,328 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,484 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $4,017 |
| Omeprazole | 86 | $2,390 |
| Atorvastatin Calcium | 342 | $2,088 |
| Diclofenac Sodium | 40 | $1,858 |
| Gabapentin | 65 | $1,511 |
| Losartan Potassium | 206 | $1,295 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 11 | $1,243 |
| Metformin Hcl | 160 | $1,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $45,94745 claims |
| Novo NordiskOzempic | $188 | $43,99729 claims |
| AstraZenecaFarxiga, Symbicort | $307 | $39,88943 claims |
| MerckJanuvia | $54 | $30,80722 claims |
| Boehringer IngelheimJardiance | $179 | $27,37516 claims |
| AbbVieLinzess, Synthroid | $154 | $20,02226 claims |
| Lilly USA, LLCHumulin 70-30 | $477 | $1,24311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 98 adult medicine providers in Texas.
Other adult medicine in Dallas
- Jordan EssenburgDallas$2K
- James Lugo RodriguezDallas$937
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
- Francisco Vera AdamesSpring$11K
- Latisha RoweHouston$11K
- Hong XiaoCarrollton$10K
- Mark NovasSheppard Afb$9K
- Daisy ArceWeslaco$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.